aTyr Pharma, Inc. Stock Analysis & AI Score
aTyr Pharma, Inc. (ATYR) has an ST Score of 36.5 (C), driven by its Forecast (A+) and held back by its Profitability (F). Analysts rate it Hold with a $5.13 price target (+2860.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIATYR Stock Price History
ATYR Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
ATYR Latest Stock News
ST Score
aTyr Pharma, Inc. (ATYR) has an ST Score of 36.5 (C), driven by its Forecast (A+) and held back by its Profitability (F). Analysts rate it Hold with a $5.13 price target (+2860.2% upside).
- Strongest
- ForecastA+
- Weakest
- ProfitabilityF
All factor grades
- ForecastA+
- GrowthB
- ValuationC
- Financial StrengthD+
- MomentumD
- ProfitabilityF
- Piotroski2/9
Press Releases
Company Contact Details
ATYR stock: frequently asked questions
What is ATYR's ST Score?
aTyr Pharma, Inc. (ATYR) has an ST Score of 36.5 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ATYR a buy, hold, or sell?
Analysts rate ATYR a Hold, with a price target of $5.13 (+2860.2% vs the current price). Our ST Score grades it C (36.5/100). The ST Score is a data-driven signal, not a recommendation.
What are ATYR's factor grades?
Valuation C, Profitability F, Financial Strength D+, Momentum D, Growth B, Forecast A+.
What is ATYR's valuation grade?
aTyr Pharma, Inc. (ATYR) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ATYR's growth grade?
aTyr Pharma, Inc. (ATYR) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ATYR's profitability grade?
aTyr Pharma, Inc. (ATYR) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ATYR's financial strength grade?
aTyr Pharma, Inc. (ATYR) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ATYR?
The average analyst price target for aTyr Pharma, Inc. (ATYR) is $5.13 from 10 analysts, which is +2860.2% versus the recent price of $0.17.
What is ATYR's Piotroski score?
aTyr Pharma, Inc. (ATYR) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.